semaglutide and ovulation Can Cause Infertility? Evidence Guidance Injectable Semaglutide Shows Early Potential

The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity

"GLP-1 isn't a strategy," she explains

The pivotal SURPASS clinical trial program for type 2 diabetes enrolled over 10,000 participants across multiple international sites, demonstrating tirzepatide's efficacy across a range of baseline characteristics and disease severities

Direct effects on liver and lipid metabolism Some research suggests that GLP-1 drugs affect how the liver makes, stores, and clears lipids

[5] Some participants also reported feeling less hungry